VIMPAT Film-coated tablet Ref.[8018] Active ingredients: Lacosamide

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium

Product name and form

Vimpat 50 mg film-coated tablets.

Vimpat 100 mg film-coated tablets.

Vimpat 150 mg film-coated tablets.

Vimpat 200 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet.

Vimpat 50 mg film-coated tablets: Pinkish, oval film-coated tablets with approximate dimensions of 10.4 mm x 4.9 mm, and debossed with ‘SP’ on one side and ‘50’ on the other side.

Vimpat 100 mg film-coated tablets: Dark yellow, oval film-coated tablets with approximate dimensions of 13.2 mm x 6.1 mm, and debossed with ‘SP’ on one side and ‘100’ on the other side.

Vimpat 150 mg film-coated tablets: Salmon, oval film-coated tablets with approximate dimensions of 15.1 mm x 7.0 mm, and debossed with ‘SP’ on one side and ‘150’ on the other side.

Vimpat 200 mg film-coated tablets: Blue, oval film-coated tablets with approximate dimensions of 16.6 mm x 7.8 mm, and debossed with ‘SP’ on one side and ‘200’ on the other side.

Qualitative and quantitative composition

Vimpat 50 mg film-coated tablets: Each film-coated tablet contains 50 mg lacosamide.

Vimpat 100 mg film-coated tablets: Each film-coated tablet contains 100 mg lacosamide.

Vimpat 150 mg film-coated tablets: Each film-coated tablet contains 150 mg lacosamide.

Vimpat 200 mg film-coated tablets: Each film-coated tablet contains 200 mg lacosamide.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Lacosamide

Lacosamide is a functionalised amino acid. The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated.

List of Excipients

Tablet core:

Microcrystalline cellulose
Hydroxypropylcellulose
Hydroxypropylcellulose (low substituted)
Silica, colloidal, anhydrous
Crospovidone (polyplasdone XL-10 Pharmaceutical Grade)
Magnesium stearate

Tablet coat:

Vimpat 50 mg film-coated tablets:

Polyvinyl alcohol
Polyethylene glycol 3350
Talc
Titanium dioxide (E171)
Red iron oxide (E172)
Black iron oxide (E172)
Indigo carmine aluminium lake (E132)

Vimpat 100 mg film-coated tablets:

Polyvinyl alcohol
Polyethylene glycol 3350
Talc
Titanium dioxide (E171)
Yellow iron oxide (E172)

Vimpat 150 mg film-coated tablets:

Polyvinyl alcohol
Polyethylene glycol 3350
Talc
Titanium dioxide (E171)
Yellow iron oxide (E172)
Red iron oxide (E172)
Black iron oxide (E172)

Vimpat 200 mg film-coated tablets:

Polyvinyl alcohol
Polyethylene glycol 3350
Talc
Titanium dioxide (E171)
Indigo carmine aluminium lake (E132)

Pack sizes and marketing

Vimpat 50 mg film-coated tablets:

Packs of 14, 28, 56 and 168 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.

Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.

Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.

Vimpat 100 mg film-coated tablets:

Packs of 14, 28, 56 and 168 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.

Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.

Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.

Vimpat 150 mg film-coated tablets:

Packs of 14, 28 and 56 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.

Multipacks containing 168 (3 packs of 56 tablets) film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.

Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.

Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.

Vimpat 200 mg film-coated tablets:

Packs of 14, 28 and 56 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.

Multipacks containing 168 (3 packs of 56 tablets) film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.

Packs of 14 × 1 and 56 × 1 film-coated tablets in PVC/PVDC perforated unit dose blisters sealed with an aluminium foil.

Packs of 60 film-coated tablets in HDPE bottle with a child-resistant closure.

Not all pack sizes may be marketed.

Marketing authorization holder

UCB Pharma S.A., Allée de la Recherche 60, B-1070, Bruxelles, Belgium

Marketing authorization dates and numbers

EU/1/08/470/001
EU/1/08/470/002
EU/1/08/470/003
EU/1/08/470/004
EU/1/08/470/005
EU/1/08/470/006
EU/1/08/470/007
EU/1/08/470/008
EU/1/08/470/009
EU/1/08/470/010
EU/1/08/470/011
EU/1/08/470/012
EU/1/08/470/020
EU/1/08/470/021
EU/1/08/470/022
EU/1/08/470/023
EU/1/08/470/024
EU/1/08/470/025
EU/1/08/470/026
EU/1/08/470/027
EU/1/08/470/028
EU/1/08/470/029
EU/1/08/470/030
EU/1/08/470/031
EU/1/08/470/032
EU/1/08/470/033
EU/1/08/470/034
EU/1/08/470/035

Date of first authorisation: 29 August 2008
Date of latest renewal: 31 July 2013

Drugs

Drug Countries
VIMPAT Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.